FOR THE BIGGER IN VITRO (IVD) COMPANIES, the third quarter (Q3) ending Sept. 30 was a time when diagnostic sales rose—molecular testing is skyrocketing, actually—while other corporate divisions continued to lag amid the COVID-19 pandemic. Here are recaps of Q3 earnings reports and investor calls from leading companies serving clinical laboratories with instrument platforms, diagnostic …
IVD Firms Report Robust Growth In Third Quarter Financial Reports Read More »
